Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Common Equity (2020 - 2025)

Rapid Micro Biosystems' Common Equity history spans 6 years, with the latest figure at $44.3 million for Q3 2025.

  • For Q3 2025, Common Equity fell 47.46% year-over-year to $44.3 million; the TTM value through Sep 2025 reached $44.3 million, down 47.46%, while the annual FY2024 figure was $75.4 million, 36.14% down from the prior year.
  • Common Equity for Q3 2025 was $44.3 million at Rapid Micro Biosystems, down from $54.5 million in the prior quarter.
  • Across five years, Common Equity topped out at $234.7 million in Q3 2021 and bottomed at -$164.5 million in Q2 2021.
  • The 5-year median for Common Equity is $118.0 million (2023), against an average of $102.5 million.
  • The largest YoY upside for Common Equity was 306.25% in 2021 against a maximum downside of 59.38% in 2021.
  • A 5-year view of Common Equity shows it stood at $221.0 million in 2021, then dropped by 25.71% to $164.2 million in 2022, then decreased by 28.13% to $118.0 million in 2023, then plummeted by 36.14% to $75.4 million in 2024, then tumbled by 41.17% to $44.3 million in 2025.
  • Per Business Quant, the three most recent readings for RPID's Common Equity are $44.3 million (Q3 2025), $54.5 million (Q2 2025), and $65.5 million (Q1 2025).